Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
Rhea-AI Summary
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer treatments, has announced its participation in the Wedbush PacGrow Healthcare Conference. The event is scheduled for Tuesday, August 13, 2024, at 11 AM ET in New York City.
This conference provides Compass Therapeutics with an opportunity to showcase its progress in developing innovative oncology therapies. As a company dedicated to creating proprietary antibody-based therapeutics for multiple human diseases, Compass's participation in this healthcare conference could offer valuable insights into its current projects and future plans in the biotechnology sector.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CMPX declined 6.52%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM ET.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Senior Communications Manager
media@compasstherapeutics.com
617-500-8099
FAQ
When and where is Compass Therapeutics (CMPX) presenting at the Wedbush PacGrow Healthcare Conference?
What type of company is Compass Therapeutics (CMPX)?
What is the focus of Compass Therapeutics' (CMPX) research and development?
What stock exchange is Compass Therapeutics (CMPX) listed on?
